РАЗХОДИ НА НЗОК ЗА ЛЕКАРСТВЕНИ ПРОДУКТИ, ЗАПЛАЩАНИ ПО РЕДА НА ЗЗО – СЪСТОЯНИЕ И ТЕНДЕНЦИИ
EXPENDITURES FOR MEDICINES, PAID BY NHIF IN ACCORDANCE WITH THE HEALTH INSURANCE LAW - STATUS AND TRENDS

Author(s): Silvia Terezova, Mariya Vasileva
Subject(s): Economy, National Economy, Business Economy / Management
Published by: Икономически университет - Варна
Keywords: International non-patent name (INN); National Health Insurance Fund (NHIF); reimbursement value; Positive Drug List (PDL)
Summary/Abstract: The medicinal products prices regulation is one of the mechanisms for reduction the publics costs. External and internal price referencing applies. The dynamics of the public expenditures changes for the medicinal products included in the PDL was assessed by month of 2022. Based on the grouping of the annual expenditures by diseases, their structure was evaluated in order to determine the costliest diseases – rare diseases. The impact of changes in the reference value of medicinal products for the treatment of two rare diseases on the NHIF costs was evaluated, by grouping them by INN with the most significant reduction of the reference value during the considered period.

• Details
• Contents